This analysis compared the costs and benefits of tamoxifen for women with early breast cancer. The main question addressed was: what are the costs and benefits of the use of tamoxifen as an adjuvant treatment in terms of survival and disease free survival for women? Survival and disease free survival estimates were based on statistical overviews of existing clinical trial data (EBCTCG 1990, 1992), and used a method (quality adjusted survival analysis) developed to analyse controlled trials where overall survival and quality of life are important. The difference in benefits between those treated with tamoxifen and the control group was measured as a difference in QALYs gained. On average, women treated with tamoxifen gained 0.405 more QALYs than the control group. Calculation of the net cost over 10 years took into account the cost of tamoxifen and the cost of recurrence for both groups. The net cost over 10 years was $553. The incremental cost per QALY gained was $1365.
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
page. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
Publisher Info
Paper provided by CHERE, University of Technology, Sydney in its series Discussion Papers with number
25.
Did you know? Citation analysis on IDEAS includes online papers that are freely accessible and whose text could be automatically analyzed, currently about 210000 papers.